

07 January 2026

Dermatology Department Biologic Drugs

Q1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs?

• Adalimumab – Humira	33
• Adalimumab Biosimilar	274
• Apremilast	7
• Bimekizumab	17
• Brodalumab	<5
• Certolizumab	8
• Deucravacitinib	<5
• Dimethyl fumarate	<5
• Etanercept – Enbrel	<5
• Etanercept Biosimilar	<5
• Guselkumab	92
• Infliximab – Remicade	<5
• Infliximab Biosimilar	13
• Ixekizumab	68
• Risankizumab	113
• Secukinumab	62
• Tildrakizumab	<5
• Ustekinumab – Stelara	<5
• Ustekinumab Biosimilar	85
• Omalizumab	36
• Spesolimab	<5

Q2. How many patients were treated in the last 3 months by the Dermatology department for HS (Hidradenitis Suppurativa) ONLY with the following?

• Adalimumab – Humira	10
• Adalimumab Biosimilar	36
• Bimekizumab	<5
• Certolizumab	<5
• Infliximab – Remicade	<5
• Infliximab Biosimilar	8
• Secukinumab	13
• Ustekinumab – Stelara	<5
• Ustekinumab Biosimilar	<5

We are unable to provide an exact figure where numbers are very low. To provide this level of information would reduce numbers to discoverable limits where the patients could be identifiable.

07 January 2026

This is exempt from release under Section 40(2) of the Freedom of Information Act - Personal Information relating to a third party.

Disclosure would constitute a breach of the principles of the Data Protection Act 2018.